Table 1 In-hospital mortality and morbidities in infants with HIE who received methylxanthines.

Death—% (no. infants)

14 (4/28)

20 (4/20)

10 (557/5443)

7–29^{12,13,15,16,17}

Length of hospital stay—days

 Median

20

16

14

12–20^12,13,17

 5th–95th percentiles

8–45

8–31

8–46

–

Feeding—% (no. infants)

 Gastrostomy tube placement

7 (2/30)

0 (0/24)

6 (347/5857)

7–9^12,13,17

Hepatic—% (no. infants)

 Coagulopathy (PT > 16 s)

91 (10/11)

86 (18/21)

80 (2612/3260)

41¹³

 Hepatic Dysfunction (AST > 200 U/L and ALT > 100 U/L)

39 (7/18)

40 (8/20)

39 (1693/4298)

20–47^12,16,17

Neurologic—% (no. infants)

 Received AED in first postnatal week

37 (11/30)

42 (10/24)

44 (2565/5857)

44–80^12,16

 Received > 1 AED in first postnatal week

13 (4/30)

13 (3/24)

10 (561/5857)

–

Pulmonary—% (no. infants)

 Receiving mechanical ventilation for ≥ 5 days

23 (7/30)

29 (7/24)

26 (1530/5857)

16^17a

Renal

 Creatinine rise > 0.3 mg/dL in 2-day period—% (no. infants)

19 (4/21)

41 (9/22)

15 (601/4134)

10^17b–65^16c

 Peak creatinine

 Median

1.00

1.25

0.91

–

 5th–95th percentiles

0.63–1.78

0.65–3.01

0.51–1.93

–